Evolent Health (NYSE:EVH) Price Target Cut to $4.00 by Analysts at Citigroup

Evolent Health (NYSE:EVH) had its price objective cut by Citigroup from $6.00 to $4.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the technology company’s stock.

EVH has been the subject of a number of other research reports. UBS Group reduced their target price on shares of Evolent Health from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday. Stephens raised shares of Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 price objective on the stock in a research report on Thursday, November 13th. Canaccord Genuity Group reduced their target price on shares of Evolent Health from $16.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 14th. BMO Capital Markets reissued an “outperform” rating and set a $3.50 price objective on shares of Evolent Health in a report on Wednesday. Finally, Royal Bank Of Canada decreased their target price on Evolent Health from $5.00 to $3.00 and set a “sector perform” rating on the stock in a research note on Wednesday. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $6.50.

Evolent Health Stock Up 6.1%

NYSE:EVH opened at $3.33 on Thursday. The company has a market cap of $371.63 million, a PE ratio of -0.65 and a beta of 0.27. Evolent Health has a 52-week low of $2.50 and a 52-week high of $12.06. The stock has a 50-day simple moving average of $3.50 and a 200 day simple moving average of $5.84. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.33 and a current ratio of 1.33.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Tuesday, February 24th. The technology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. The firm had revenue of $468.72 million during the quarter, compared to analysts’ expectations of $468.48 million. Evolent Health had a positive return on equity of 1.30% and a negative net margin of 28.49%.The business’s quarterly revenue was down 27.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.02) earnings per share. On average, sell-side analysts expect that Evolent Health will post 0.08 EPS for the current fiscal year.

Institutional Trading of Evolent Health

Several institutional investors and hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its stake in Evolent Health by 88.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock worth $29,000 after purchasing an additional 1,194 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in Evolent Health by 10.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 27,242 shares of the technology company’s stock valued at $307,000 after buying an additional 2,666 shares in the last quarter. Cetera Trust Company N.A lifted its position in Evolent Health by 47.3% during the 2nd quarter. Cetera Trust Company N.A now owns 9,725 shares of the technology company’s stock worth $110,000 after acquiring an additional 3,125 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Evolent Health by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company’s stock valued at $1,217,000 after acquiring an additional 3,572 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its holdings in shares of Evolent Health by 4,000.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock valued at $35,000 after purchasing an additional 4,000 shares in the last quarter.

Key Stories Impacting Evolent Health

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 earnings beat — Evolent posted $0.08 EPS vs. consensus $0.06, turning profitable year-over-year and giving investors a near-term catalyst. Evolent Health (EVH) Q4 Earnings Top Estimates
• Positive Sentiment: Management to participate in investor conferences with live webcasts — increases visibility and gives investors direct access to management’s strategy and outlook. Evolent to Participate in Upcoming Investor Conferences
• Positive Sentiment: Some analysts maintain buy ratings and still show upside — BTIG (new $8 PT) and UBS (new $5 PT) kept buy calls, signaling continued institutional conviction despite lower targets. Evolent Health (NYSE:EVH) Given New $8.00 Price Target at BTIG Research
• Neutral Sentiment: Market commentary and analysis highlight turnaround potential and technical momentum — pieces noting EVH as “cheap, levered, but ready to rebound” and coverage of the intraday move provide narrative context rather than new fundamentals. Evolent Health: Cheap, Levered, But Ready To Rebound
• Neutral Sentiment: Investor note/roundups covering the share move summarize news flow for traders but don’t add new company data. Evolent Health (EVH) Shares Skyrocket, What You Need To Know
• Negative Sentiment: Multiple price-target cuts and a downgrade — several firms lowered PTs (Needham, Citi, RBC, UBS) and KeyCorp downgraded EVH to sector weight, which increases near-term downside risk and reflects investor concerns about top-line declines and leverage. Benzinga coverage of analyst actions
• Negative Sentiment: Revenue decline and margin pressure remain issues — revenue was roughly flat to consensus but down year-over-year, and the company still reports negative net margins, which could limit investor enthusiasm absent clear margin improvement. Evolent Health, Inc. Q4 2025 Earnings Call Transcript

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.